ArticleKidney medicine2024
A Review of Focal Segmental Glomerulosclerosis Classification With a Focus on Genetic Associations.
Article in Kidney medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial.Clinical journal of the American Society of Nephrology : CJASN · 2026Trial
- Sparsentan Versus Irbesartan in Pediatric Patients With FSGS.Kidney international reports · 2026Article
- Anti-nephrin antibodies are not enriched in patients with primary and posttransplant recurrent podocytopathies.The Journal of clinical investigation · 2026Observational
- The Importance of Molecular Testing in the Diagnosis of Genetic Syndromes with Chronic Kidney Disease: Genotype-Phenotype Correlations.International journal of molecular sciences · 2026Article
- Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Overlap of PR3-Positive ANCA-Associated Vasculitis and Primary Focal Segmental Glomerulosclerosis: A Case Report, Patient Perspective, and Review of the Literature.Canadian journal of kidney health and disease · 2026Article
- A Novel CRB2 Mutation Associated With FSGS and ESRD in an Adult Patient.Case reports in nephrology · 2026Article
- Diagnostic and prognostic signatures of glomerular membrane dysregulation in immune nephropathies.Frontiers in immunology · 2026Article
- Podocytopathies.Nature reviews. Disease primers · 2025Review
- Temporal and Demographic Trends in Biopsy-Proven Kidney Disease Diagnoses in the Southwestern United States, 1993-2022.Kidney medicine · 2025Article
- New and Emerging Nonimmunosuppressive Drug Therapies for Primary Adult Glomerular Diseases.Kidney medicine · 2025Review
- Identification and experimental validation of autophagy-related genes in focal segmental glomerulosclerosis by integrating bioinformatics and machine learning.Scientific reports · 2025Article
- Review
- Patterns of Glomerular Injury: Histopathological Classification and Clinical Correlation.Cureus · 2025Review
- Intersecting transcriptomic landscapes of hypertension and kidney function in African American women.American journal of physiology. Renal physiology · 2025Article
- Renal tubular acidosis: Varied aetiologies and clinical presentations: Three case reports.World journal of nephrology · 2025Article
- Evaluation for genetic disease in kidney transplant candidates: A practice resource.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025Review
- Successful Management of Relapsing Primary Focal Segmental Glomerulosclerosis With Tacrolimus and Mycophenolate Multitarget Therapy.Case reports in nephrology · 2025Article
- Beyond Antibodies in Post-Transplant FSGS: New Answers or Recurrent Questions?Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Focal Segmental Glomerulosclerosis With Superimposed Infection-Related Glomerulonephritis in a Diabetic Patient: A Case of Rapid Renal Decline.Clinical case reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal segmental glomerulosclerosis (FSGS) defines a distinct histologic pattern observed in kidney tissue that is linked to several distinct underlying causes, all converging on the common factor of podocyte injury. It presents a considerable challenge in terms of classification because of its varied underlying causes and the limited correlation between histopathology and clinical outcomes. Critically, precise nomenclature is key to describe and delineate the pathogenesis, subsequently guiding the selection of suitable and precision therapies. A proposed pathomechanism-based approach has been suggested for FSGS classification. This approach differentiates among primary, secondary, genetic, and undetermined causes, aiming to provide clarity. Genetic FSGS from monogenic mutations can emerge during childhood or adulthood, and it is advisable to conduct genetic testing in cases in which there is a family history of chronic kidney disease, nephrotic syndrome, or resistance to treatment. Genome-wide association studies have identified several genetic risk variants, such as those in apolipoprotein L1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.